Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

• Authors: BLADÉ Joan; SONNEVELD Pieter; SAN MIGUEL Jesús F.; SUTHERLAND Heather J.; HÁJEK Roman; NAGLER Arnon; SPENCER Andrew; ROBAK Tadeusz; LANTZ Keith C.; ZHUANG Sen H.; HAROUSSEAU Jean-Luc; ORLOWSKI Robert Z.
• Year of publication: 2011
• Type: Article in Periodical
• Magazine / Source: Clinical lymphoma, myeloma & leukemia
• MU Faculty or unit: Faculty of Medicine
• Doi: https://doi.org/10.3816/CLML.2011.n.005
• Field: Oncology and hematology
• Keywords: Clinical outcomes; Multiple myeloma;Relapsed; refractory disease
• Description: Introduction: Bortezomib with pegylated liposomal doxorubicin (PLD) is superior to bortezomib alone in the relapsed and/or refractory setting, based on the results of a randomized, parallel-group, open-label, multicenter phase III study. To identify patients who might most benefit from this new standard of care, we performed retrospective analyses evaluating the effects of clinically defined, high-risk features on the outcomes with this regimen. Treatment of relapsed/refractory myeloma with the combination of PLD plus bortezomib provides better outcomes over bortezomib alone, even in the presence of high-risk prognostic factors. These results suggest that PLD plus bortezomib may represent an additional standard of care for this population of patients with multiple myeloma.